Pharmacophore-Based Design of Novel Oxadiazoles as Selective Sphingosine-1-phosphate (S1P) Receptor Agonists with in vivo Efficacy
- 3 March 2015
- journal article
- Published by Wiley in ChemMedChem
- Vol. 10 (4) , 688-714
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyondNature Reviews Drug Discovery, 2013
- The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rateBritish Journal of Pharmacology, 2012
- Crystal Structure of a Lipid G Protein–Coupled ReceptorScience, 2012
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011
- Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar SlicesThe American Journal of Pathology, 2010
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemBritish Journal of Pharmacology, 2009
- Full Pharmacological Efficacy of a Novel S1P1 Agonist That Does Not Require S1P-Like Headgroup InteractionsMolecular Pharmacology, 2008
- The alliance of sphingosine-1-phosphate and its receptors in immunityNature Reviews Immunology, 2008
- BML‐241 fails to display selective antagonism at the sphingosine‐1‐phosphate receptor, S1P3British Journal of Pharmacology, 2006